Q1 2020 January-March Business review President and CEO Hannu Martola | 27 April 2020
Slide 2: Q1 2020 key figures: net sales and EBIT
Q1 2020 › 19.9 -13.6 1.2 5.9 net sales, €m net sales change-% EBIT, €m EBIT-% (23.1) (19.3) (3.9) (16.7) 2 27.4.2020 Detection Technology | Business review January-March 2020
Slide 3: Demand and profitability weakened by COVID-19
Q1 2020 › Demand and profitability weakened by COVID-19, however succeeded in minimizing adverse effects of the pandemic on DT business COVID-19-risks realized in the security market, and SBU sales decreased as Asia got the hit first Medical CT demand grew towards the end of Q1 driven by the pandemi
Slide 6: Sales split Q1 2020 by business unit and region
SALES SPLIT Q1 2020 BY BUSINESS UNIT › BY REGION › 22% 42% NET SALES NET SALES 19.9 19.9 €m 58% 17% €m 62% MBU SBU APAC -13.9 8.4 NET SALES €m 11.5 NET SALES €m AMERICAS -12.7 Y-O-Y CHANGE-% -2.3 -20.3 Y-O-Y CHANGE-% EMEA -13.6 Y-O-Y CHANGE-% 6 27.4.2020 Detection Technology | Business review Januar
STRATEGY › Received customer validation for X-Panel, start of sales for dental applications in Q2 2020 Strengthened its competitive position in the line-scan segment thanks to Aurora Progressed with the key projects of the multi-energy (ME) product line, aims to start commercial production by the en
Slide 9: Business outlook
BUSINESS OUTLOOK 5% 6% 5% MEDICAL MARKET SECURITY MARKET INDUSTRIAL MARKET annual growth rate annual growth rate annual growth rate • COVID-19 has disrupted market dynamics, DT opines that, apart from medical CT imaging, annual growth will remain lower than the aforementioned industry estimates in 2
Slide 10: Financial targets
FINANCIAL TARGETS › MEDIUM TERM Annual MEDIUM TERM Operating ANNUAL Dividend or sales growth margin returned capital >10% ≥15% 30-60% 10 27.4.2020 Detection Technology | Business review January-March 2020